Xbrane Biopharma AB (publ) (XBRANE.ST)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Martin Amark | Chief Executive Officer | 3.28M | -- | 1980 |
| Mr. Siavash Bashiri | COO, Head of Biosimilars & Deputy CEO | 1.79M | -- | 1983 |
| Associate Prof. Jan-Willem De Gier | Co-Founder | -- | -- | -- |
| Dr. Samuel Wagner Ph.D. | Co-Founder & Member of Scientific Advisory Board | -- | -- | -- |
| Ms. Anette Lindqvist | CFO & Head of Investor Relations | -- | -- | 1961 |
| Dr. David Vikstr?m | Chief Technology Officer | -- | -- | 1977 |
| Ms. Dina Jurman | Head of Clinical Affairs | -- | -- | 1982 |
| Mr. Anders Wallstr?m | Head of Manufacturing & Supply Chain | -- | -- | 1976 |
| Mr. H?kan Yildirim | Head of Intellectual Property | -- | -- | -- |
Xbrane Biopharma AB (publ)
- Sector:?
- Healthcare
- Industry:? Biotechnology
- Full Time Employees:?
- 71
Description
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults. Its pre-clinical phase products include BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis, Crohn's disease, and axial spondylitis; Xdivane, a nivolumab biosimilar candidate, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; and Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma. The company was incorporated in 2008 and is headquartered in Solna, Sweden.
Corporate Governance
Upcoming Events
October 24, 2024 at 10:59 AM UTC
Xbrane Biopharma AB (publ) Earnings Date
Recent Events
Recent Events Information Not Available